Alumis
ALMS
Performance
About Alumis
Alumis is a biotechnology company focused on developing therapies for immune-mediated diseases. Based in the San Francisco Bay Area, it advances a late-stage portfolio of targeted, precision therapeutics designed to improve patient outcomes across conditions such as lupus and psoriasis. The company emphasizes integrating scientific insights with a proprietary data analytics platform to accelerate therapeutic development. Alumis’ leadership and operations are anchored in South San Francisco, California.
Recent News
The 5 Largest IPOs in Biopharma History
Aardvark's Next Move After Clinical Hold; Alumis' Verdict on Acelyrin Asset
Omega Fund Management Boosts Bicara Therapeutics Stake to 29% with $3.2M Purchase
Alumis Soars as TYK2 Drug Hits Mark in Psoriasis Trials
VIDEO: ‘New Era of Oral Therapies’ on Horizon in Psoriasis
The Biggest Biotech Funding Rounds in January 2026
‘Over and Above’ Responses Seen with Envudeucitinib for Plaque Psoriasis
Alumis’ Phase III TYK2 Data Intensify Psoriasis Efficacy Contest
Recent Deals
No recent deals for this company.